Pancreatic Cancer Research

ResearcherKanazawa UniversityActive in the last 2 years

Isamu Makino

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6023-7163; OpenAlex author ID A5015560023. Sources: OpenAlex.

Their work

Papers
25 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: 4 papers · 2014: 1 paper · 2015: none · 2016: none · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 3 papers · 2022: 1 paper · 2023: none · 2024: 4 papers · 2025: none · 2026: 3 papers

Papers 25

  1. International multicenter validation of an 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake value 4.0 thresh… Co-author DOI 10.1016/j.surg.2026.110503↗
  2. RAGE signaling inhibition prevents the malignant phenotypes of pancreatic ductal adenocarcinoma cells. Co-author DOI 10.1038/s41598-026-48913-5↗
  3. Prognostic significance of fibroblast senescence and senescence-associated secretory phenotype factor expression in the tumor microenvironment of pancreatic du… Co-author DOI 10.3892/or.2025.9031↗
  4. Clinical impacts of positive intraepithelial neoplasia at pancreatic transection margin in pancreatic cancer surgery. First author DOI 10.1016/j.pan.2024.02.005↗
  5. Morphology of the Dorsal Pancreatic Artery and Its Oncological Significance in Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000002327↗
  6. [Two Cases of Portal Vein Stent Placement for Portal Vein Stenosis Due to Recurrence of Pancreatic Cancer]. Co-author PMID 38449416↗
  7. Enhanced Germinal Center Reactions Within Tertiary Lymphoid Structures Following Neoadjuvant Chemotherapy and Intestinal Care-A Path to Robust Antitumor Immune… First author PMID 39571990↗
  8. Verification of Resectability Status for Pancreatic Cancer: Radiological and Pathological Analysis of Patients Undergoing Pancreatoduodenectomy With Combined R… Co-author DOI 10.1097/mpa.0000000000001964↗
  9. A phase I study of preoperative (neoadjuvant) chemotherapy with gemcitabine plus nab-paclitaxel for resectable pancreatic cancer. First author DOI 10.3892/mco.2020.2188↗
  10. [Intestinal Care Using L‒Glutamine Supplement and Probiotics Can Induce a Strong Anti‒Tumor Immune Response through the Induction of Mature Tertiary Lymphoid S… First author PMID 33976027↗
  11. Dysbiotic gut microbiota in pancreatic cancer patients form correlation networks with the oral microbiota and prognostic factors. Co-author PMID 34249452↗
  12. Impact of Extravasated Platelet Activation and Podoplanin-positive Cancer-associated Fibroblasts in Pancreatic Cancer Stroma. Co-author DOI 10.21873/anticanres.13750↗
  13. Phase I study of third-line palliative chemotherapy with low dose paclitaxel for pancreatic cancer. Co-author DOI 10.3892/mco.2018.1579↗
  14. [A Case of Pathological Complete Response Induced by Preoperative Chemotherapy with Gemcitabine plus Nab-Paclitaxel in a Patient with Pancreatic Cancer on Hemo… Co-author PMID 30692318↗
  15. Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreat… Co-author DOI 10.1007/s10238-015-0394-x↗
  16. Neoadjuvant chemotherapy for pancreatic cancer: Effects on cancer tissue and novel perspectives. First author DOI 10.3892/ol.2017.6008↗
  17. [A case report of hepatic arterial infusion chemotherapy and RFA for liver metastasis from pancreatic cancer]. Co-author PMID 25731471↗
  18. A phase I study of neoadjuvant chemotherapy with gemcitabine plus oral S-1 for resectable pancreatic cancer. Co-author DOI 10.3892/mco.2013.133↗
  19. Hepatic arterial infusion chemotherapy with gemcitabine and 5-fluorouracil or oral S-1 improves the prognosis of patients with postoperative liver metastases f… Co-author DOI 10.3892/mco.2013.152↗
  20. [Gemcitabine augments major histocompatibility complex class I-related chain A expression in pancreatic cancer]. Co-author PMID 24393861↗
  21. [Hepatic arterial infusion chemotherapy with gemcitabine for patients with postoperative liver metastases from pancreatic cancer]. Co-author PMID 24393883↗
  22. Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer. Co-author DOI 10.3892/etm.2012.482↗
  23. Neoadjuvant chemotherapy with gemcitabine for pancreatic cancer increases in situ expression of the apoptosis marker M30 and stem cell marker CD44. Co-author DOI 10.3892/ol.2012.657↗
  24. Increased E-selectin in hepatic ischemia-reperfusion injury mediates liver metastasis of pancreatic cancer. Co-author DOI 10.3892/or.2012.1896↗
  25. Pilot study of hepatic arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for patients with postoperative liver metastases from pancreatic canc… Co-author DOI 10.3892/etm.2011.190↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mitsuyoshi Okazaki · 11 shared papers, 2018–2026 · strength 1.81
  2. Shintaro Yagi · 7 shared papers, 2024–2026 · strength 1.71
  3. Tetsuo Ohta · 19 shared papers, 2011–2024 · strength 1.49
  4. Tomoharu Miyashita · 13 shared papers, 2013–2026 · strength 1.08
  5. Hidehiro Tajima · 17 shared papers, 2011–2022 · strength 0.98
  6. Satoshi Takada · 4 shared papers, 2024–2026 · strength 0.89
  7. Itasu Ninomiya · 11 shared papers, 2011–2022 · strength 0.57
  8. Yuto Kitano · 1 shared paper, 2026 · strength 0.32
  9. Takeo Shimasaki · 1 shared paper, 2026 · strength 0.32
  10. Hironori Minami · 1 shared paper, 2026 · strength 0.28
  11. Hirotaka Yuki · 1 shared paper, 2024 · strength 0.21
  12. Takahiro Kyuno · 1 shared paper, 2024 · strength 0.20
  13. Atsushi Tomioka · 1 shared paper, 2026 · strength 0.19
  14. Teiichi Sugiura · 1 shared paper, 2026 · strength 0.19
  15. Yoo‐Seok Yoon · 1 shared paper, 2026 · strength 0.19
  16. Tetsuya Idichi · 1 shared paper, 2026 · strength 0.19
  17. Kousei Ishigami · 1 shared paper, 2026 · strength 0.19
  18. Hongbeom Kim · 1 shared paper, 2026 · strength 0.19
  19. Hyung Il Seo · 1 shared paper, 2026 · strength 0.19
  20. Shigeru Marubashi · 1 shared paper, 2026 · strength 0.19
  21. Naru Kim · 1 shared paper, 2026 · strength 0.19
  22. Minoru Oshima · 1 shared paper, 2026 · strength 0.19
  23. Munseok Choi · 1 shared paper, 2026 · strength 0.19
  24. Masayuki Tanaka · 1 shared paper, 2026 · strength 0.19
  25. Katsuhisa Ohgi · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.